Showing results (51-60 of 238) with videos related to
Sort By:
Pageof 24
The Oncologist|May 30, 2014
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRASandra M Swain, Young-Hyuck Im, Seock-Ah Im, et al.Journal of the National Cancer Institute|August 21, 2014
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancerAleix Prat, Lisa A Carey, Barbara Adamo, et al.Cancer Discovery|December 6, 2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signalingVanessa S Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C Pagano, et al.Lung Cancer (Amsterdam, Netherlands)|February 24, 2009
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinibSusana Cedrés, Aleix Prat, Pablo Martínez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJan B Vermorken, José Trigo, Ricardo Hitt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJosé Baselga, José M Trigo, Jean Bourhis, et al.Trials|July 24, 2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trialJosé Baselga, Frederico Costa, Henry Gomez, et al.The EMBO Journal|August 3, 2016
The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growthRuzica Bago, Eeva Sommer, Pau Castel, et al.The Oncologist|March 12, 2013
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III studySandra M Swain, Michael S Ewer, Javier Cortés, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targetingPablo Matar, Federico Rojo, Raúl Cassia, et al.Pageof 24